ATUM

miFuc® Platform for Antibodies with Increased ADCC activity

Enabled by Leap-In Transposase

Functional in any cell line

Flexible and dynamic platform



Reduction in core fucose within any cell line

Features:

- Host cell agnostic, can use any host cell line
- Mechanism delivered within expression vector
- Enabled by Leap-In Transposase based integration
- Stable phenotype once pools and clones are selected





Benefits:

- Extremely flexible platform:
  - Compatible with various host cell lines
  - Works across multiple vector configurations
- Significant reduction in fucosylated mAbs without global glycan liabilities

Enhanced ADCC activity



Uniquely enabling bulk pools:

- Significantly increased CD16 based signaling (ADCC)
- Robust and reproducible activity

References:

Rajendran et.al., Biotechnol. Bioeng., 2021, 118(6):2301-2311

Protected by more than 10 issued patents

The Leap-In Transposase® and miFuc® platforms are available for licensing or as a service provided by ATUM. Contact us for more information:

+1 650 853 8347

+1 877 DNA TOGO

info@atum.bio

ATUM

Your Life Science partner

37950 Central Court
Newark, CA 94560
U.S.A.

+1 877 DNA TOGO
+1 650 853 8347
info@atum.bio
www.atum.bio

SCAN ME



research. create. break through.